Despite the setback, ProKidney remains optimistic about its prospects. The company plans to present detailed data from the Phase III trial at upcoming medical conferences, which could provide valuable insights for future research and development efforts. Additionally, ProKidney is exploring potential partnerships and collaborations to further its mission of improving outcomes for CKD patients.